Cortechs.ai | Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant<sup>®</sup>

Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai expands market reach into Canada for NeuroQuant, the leading volumetric brain imaging solution for MRIs.

(SAN DIEGO) Feb. 2, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received Health Canada/Santé Canada Medical Device License for marketing and distribution of NeuroQuant® in Canada. Already FDA cleared and CE marked, NeuroQuant is used throughout the world by physicians in hundreds of reputable clinics and hospitals to help in their assessment of neurodegeneration.

Fully automated, NeuroQuant provides neurologists, radiologists, and clinical researchers with an accurate and convenient tool to quantify the volumes of specific brain structures in order to better assess neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

“The Heath Canada/Santé Canada Medical Device License is a testament to our commitment to quality, safety and performance and now allows customers in Canada to start using NeuroQuant in their clinical practice,” commented Guri Stark, CEO of Cortechs.ai. “We are excited to introduce our innovative brain imaging solution to Canadian hospitals, clinics and universities and expand access to proven and reliable quantitative volumetric analysis of neurological conditions via MR imaging.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

12/18/2025

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Our reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping inform providers.

12/10/2025

Reflections on RSNA 2025 and What We Learned at the Cortechs.ai Booth 

If there was one overall takeaway from RSNA 2025, it’s that clinicians are ready for tools that reduce manual work and make reporting more consistent.

12/09/2025

Dementia Imaging: Case-based PET/MRI Approach

Join us for a webinar that will unlock the latest insights in dementia imaging with Dr. Ana M. Franceschi, MD PhD.

12/09/2025

SNO 2025 Recap: Collaboration Driving Innovation in Neuro-Oncology

The 2025 Society for Neuro-Oncology meeting was more than a conference, it was a hub of collaboration and conversation among industry leaders and physicians.

11/19/2025

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology

The companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems.

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care
Scroll to Top